Chimeric Therapeutics Ltd

CHM

Company Profile

  • Business description

    Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

  • Contact

    62 Lygon Street
    Level 3, Carlton South
    MelbourneVIC3053
    AUS

    T: +61 398245254

    https://www.chimerictherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,772.001.00-0.01%
CAC 407,662.593.32-0.04%
DAX 4023,673.29236.32-0.99%
Dow JONES (US)44,494.94400.170.91%
FTSE 1008,785.3324.370.28%
HKSE24,072.28211.87-0.87%
NASDAQ20,202.89166.84-0.82%
Nikkei 22539,986.33501.06-1.24%
NZX 50 Index12,734.53131.711.05%
S&P 5006,198.016.94-0.11%
S&P/ASX 2008,541.101.20-0.01%
SSE Composite Index3,444.4320.200.59%

Market Movers